Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Center, Open-Label, Phase 1 Study to Evaluate the Pharmacokinetics of CRV431 Under Fasted and Fed States in Normal Healthy Volunteer Subjects

Trial Profile

A Single Center, Open-Label, Phase 1 Study to Evaluate the Pharmacokinetics of CRV431 Under Fasted and Fed States in Normal Healthy Volunteer Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rencofilstat (Primary)
  • Indications Coronavirus infections; COVID 2019 infections; Hepatitis B; Hepatitis C; Hepatitis D; HIV-1 infections; Human papillomavirus infections; Liver cancer; Liver disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; SARS-CoV-2 acute respiratory disease
  • Focus Pharmacokinetics
  • Sponsors Hepion Pharmaceuticals

Most Recent Events

  • 28 Oct 2022 New trial record
  • 20 Oct 2022 According to a Hepion Pharmaceuticals media release, results from the study have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top